First Targeted Therapy for Exon 20 Insertions in NSCLC Wins FDA Accelerated Approval

(MedPage Today) — The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell lung cancer (NSCLC) associated with EGFR exon 20 insertions, the agency said.
The approval stipulates…

Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116393

Author :

Publish date : 2025-07-07 17:59:00

Copyright for syndicated content belongs to the linked Source.